

Board of Directors – 29 January 2014

Monitor Quarter 3 Return

Action requested/recommendation

To approve the proposed submission to Monitor.

<u>Summary</u>

On 1 October 2013, Monitor introduced the Risk Assessment Framework. This replaced the Compliance Framework.

From quarter 3, this quarter Monitor is now reviewing the Continuity of Services Risk Rating (COSRR) and a Governance rating.

The COSRR is on a 1-4 rating based on liquidity and capital service capacity, 4 being the best rating and 1 being the worst. A rating of 3 will result in some additional information being requested by Monitor. A rating of 4 will generally mean that no action will be taken beyond continuing to monitor the Trust. For quarter 2 the Trust will report on a dual basis – on the FRR and the COSRR.

In terms of the Governance rating, Monitor will take a number of key aspects into account, including performance, CQC judgements and third party information, quality governance information and the degree of risk to COSRR.

Monitor will assign 'green' governance rating where there are no concerns. Where potential material concerns are identified the governance rating will be replaced by a description of the concerns. If Monitor takes regulatory action a 'red' rating will be assigned.

Monitor advised the Trust that at Q2, there was a 'narrative' attached to the governance rating. This related to the performance of the 4 hour target and the level of C-Diff reported.

The papers attached are the submission for quarter 3.

St	rategic Aims	Please cross as appropriate
1.	Improve quality and safety	
2.	Create a culture of continuous improvement	
3.	Develop and enable strong partnerships	\boxtimes
4.	Improve our facilities and protect the environment	

Implications for equality and diversity

None directly identified.

Reference to CQC outcomes

No reference to CQC outcomes.

Progress of report Prepared for presentation to the Board of Directors.

Risk There are performance risks identified in the paper.

Resource implications Not directly identified.

Owner Patrick Crowley, Chief Executive

Author Anna Pridmore, Foundation Trust Secretary

Date of paper January 2014

Version number Version 1

Worksheet "Summary"

High level summary of financial plan of YORKHOSPITAL

Financial Summary	Previous YE	Current Quarter			YTD			FY
£m	Actual	Plan	Actual	Variance	Plan	Actual	Variance	Plan
Operating Revenue for EBITDA	403.7	109.5	113.9	4.4	320.1	329.7	9.7	428.0
Employee Expenses	(262.5)	(71.7)	(72.3)	(0.6)	(212.2)	(216.1)	(3.9)	(284.3)
Drugs	(30.5)	(7.8)	(8.9)	(1.1)	(23.0)	(25.8)	(2.8)	(30.8)
PFI operating expenses	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other costs	(91.7)	(24.1)	(27.3)	(3.2)	(70.1)	(73.7)	(3.6)	(94.0)
Clinical supplies	(40.4)	(11.4)	(11.6)	(0.2)	(33.6)	(33.9)	(0.3)	(45.1)
Decrease (increase) in inventories of finished goods & WIP	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Vehicle Fuel costs (ambulance trusts)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Non-clinical supplies	(6.4)	(1.7)	(2.0)	(0.3)	(5.1)	(5.7)	(0.5)	(6.9)
Cost of Secondary Commissioning of mandatory services	(3.3)	(1.2)	(0.8)	0.4	(3.5)	(2.2)	1.2	(4.6)
Research & Development expense	(4.4)	(1.2)	(1.2)	0.1	(3.7)	(3.3)	0.4	(4.9)
Education and training expense	(1.0)	(0.3)	(0.3)	(0.0)	(1.0)	(0.7)	0.3	(1.3)
Misc. other Operating expenses	(34.9)	(8.0)	(8.9)	(0.9)	(22.5)	(25.3)	(2.8)	(30.3)
EBITDA	19.1	5.9	5.5	(0.5)	14.8	14.1	(0.6)	18.9
Donations of PPE & intangible assets	0.5	0.1	0.0	(0.1)	0.4	0.0	(0.4)	0.5
Depreciation and amortisation	(8.8)	(2.7)	(2.7)	(0.0)	(8.1)	(8.1)	(0.4)	(10.9)
Impairment Losses (Reversals) net (on non-PFI assets)	(3.5)	0.0	0.0	0.0	0.0	0.0	0.0	(0.3)
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Impairment Losses (Reversals) net on PFI assets	(0.8)	0.0	(0.1)	(0.1)	0.0	(0.7)	(0.7)	0.0
Restructuring Costs	6.5							
Operating Surplus		3.3	2.6	(0.7)	7.0	5.3	(1.7)	8.2
Net interest	(0.1)	(0.1)	(0.0)	0.0	(0.1)	(0.1)	0.0	(0.2)
Interest Income	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.1
Interest Expense on Overdrafts and Working Capital Facilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Interest Expense on Bridging loans	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Interest Expense on Non-commercial borrowings	(0.2)	(0.1)	(0.1)	0.0	(0.2)	(0.2)	0.0	(0.3)
Interest Expense on Commercial borrowings	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Interest Expense on Finance leases (non-PFI)	(0.0)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Interest Expense on PFI leases & liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Operating items	63.9	(1.4)	(1.5)	(0.1)	(4.2)	(4.3)	(0.1)	(5.6)
Gain (Loss) on Financial Instruments Designated as Cash Flow Hedges	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gain (Loss) on Derecognition of Available-for-Sale Financial Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gain (Loss) on Derecognition of Non-Current Assets Not Held for Sale, Total	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gain (Loss) from investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Dividend Income	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Share of profit (loss) from equity accounted Associates, Joint Ventures, Total	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Operating income, Total	69.0	0.0	0.0	0.0	0.0	(0.0)	(0.0)	0.0
Other Finance Costs	(0.0)	0.0	(0.1)	(0.1)	0.0	(0.1)	(0.1)	0.0
PDC dividend expense	(5.0)	(1.4)	(1.4)	(0.0)	(4.2)	(4.2)	(0.0)	(5.6)
PFI Contingent Rent	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Operating expenses (incl. Misc)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Income Tax (expense)/ income	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Surplus / (Deficit)	70.4	1.9	1.1	(8.0)	2.7	1.0	(1.7)	2.4
ERITOA % Incomo	4 79/	E 49/	4 99/	0.69/	4.69/	1 20/	0.39/	4.49/
EBITDA % Income	4.7%	5.4%	4.8%	-0.6%	4.6%	4.3%	-0.3%	4.4%
CIP% of Op.Exp. less PFI Exp.	5.7%	5.3%	6.4%	1.0%	5.4%	5.0%	-0.5%	5.4%
Pay CIPs as % Pay Costs	-5.8%	-6.1%	-8.1%	-1.9%	-6.2%	-5.5%	0.7%	-6.2%

Net Surplus / (Deficit)	70.4	1.9	1.1	(0.8)	2.7	1.0	(1.7)	2.4
Change in working capital	1.8	(3.0)	(15.4)	(12.4)	(1.0)	(10.5)	(9.5)	(1.0)
(Increase)/decrease in inventories	(3.5)	0.0	(0.1)	(0.1)	0.0	(0.4)	(0.4)	0.0
(Increase)/decrease in tax receivable	0.0	0.0	0.2	0.2	0.0	0.1	0.1	0.0
(Increase)/decrease in NHS Trade Receivables	(4.0)	(3.0)	(5.0)	(2.0)	2.0	3.6	1.6	(1.0)
(Increase)/decrease in Non NHS Trade Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
(Increase)/decrease in other related party receivables	(0.8)	0.0	0.9	0.9	0.0	0.9	0.9	0.0
(Increase)/decrease in other receivables	(0.5)	0.0	(1.2)	(1.2)	0.0	(1.6)	(1.6)	0.0
(Increase)/decrease in accrued income (Increase)/decrease in other financial assets	0.4 0.0	0.0	(4.4) 0.0	(4.4) 0.0	0.0 (3.0)	(11.3) 0.0	(11.3) 3.0	0.0 0.0
(Increase)/decrease in other innancial assets (Increase)/decrease in prepayments	(0.3)	0.0	(0.9)	(0.9)	0.0	(2.2)	(2.2)	0.0
				0.0		0.0	0.0	
(Increase)/decrease in Other assets	0.0	0.0 0.0	0.0 0.0	0.0	0.0 0.0	0.0	0.0	0.0 0.0
Increase/(decrease) in Deferred Income (excl. Donated Assets) Increase/(decrease) in Deferred Income (Donated Assets)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase/(decrease) in Current provisions	0.0	0.0	0.0	0.0	0.0	(0.0)	(0.0)	0.0
Increase/(decrease) in post-employment benefit obligations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase/(decrease) in tax payable	0.0	0.0	0.1	0.1	0.0	(0.2)	(0.2)	0.0
Increase/(decrease) in Trade Creditors	4.4	0.0	(0.5)	(0.5)	0.0	(2.7)	(2.7)	0.0
Increase/(decrease) in Other Creditors	3.8	0.0	(0.0)	(0.0)	0.0	0.5	0.5	0.0
Increase/(decrease) in accruals	2.3	0.0	(2.0)	(2.0)	0.0	(1.0)	(1.0)	0.0
Increase/(decrease) in other Financial liabilities	0.0	0.0	(2.4)	(2.4)	0.0	3.6	3.6	0.0
Increase/(decrease) in Other liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase/(decrease) in Non Current provisions	0.4	0.0	0.0	0.0	0.0	(0.0)	(0.0)	0.0
Non cash I&E items	(51.5)	4.2	6.7	2.4	12.3	14.9	2.6	16.7
Tax expense/(refund)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Finance (income)/charges	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.0
Share of (profit)/loss from equity accounted investments net of cash distributions received	0.0 0.0	0.0	0.0	0.0	0.0 0.0	0.0 0.0	0.0 0.0	0.0 0.0
Donations & Grants received of PPE & intangible assets (non cash) Other operating non-cash (revenues)/expenses	0.0	0.0	2.5	2.4	0.0	2.5	2.5	(0.1)
Depreciation and amortisation, total	8.8	2.7	2.7	0.0	8.1	8.1	0.0	10.9
Impairment losses/(reversals)	3.5	0.0	0.0	0.0	0.0	0.0	0.0	0.3
Unrealised (gains)/losses on foreign currency exchange	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
(Gain)/loss on disposal of property plant and equipment	(0.0)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
(Gain)/loss on disposal of intangible assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Share of (profit)/loss loss from investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
PDC dividend expense	5.0	1.4	1.4	0.0	4.2	4.2	0.0	5.6
Other increases/(decreases) to reconcile to profit/(loss) from operations	(68.9)	0.0	(0.0)	(0.0)	0.0	(0.0)	(0.0)	0.0
Cashflow from operations	21.1	3.1	(7.6)	(10.7)	14.0	5.3	(8.6)	18.1
Cashflow from investing activities	(17.5)	(6.6)	(3.3)	3.3	(13.7)	(8.6)	5.1	(22.3)
Property, plant and equipment - maintenance expenditure	(6.7)	(2.5)	(2.0)	0.5	(5.0)	(4.8)	0.2	(8.2)
Property, plant and equipment - non-maintenance expenditure	0.0	(1.0)	0.0	1.0	(1.5)	0.0	1.5	(3.2)
Plant and equipment - Information Technology Plant and equipment - Other	(2.9) (1.8)	0.0 (2.6)	0.0 (1.1)	0.0 1.5	0.0 (4.4)	0.0	0.0 3.0	0.0 (7.6)
Property, plant and equipment - other expenditure	0.0	(0.5)	(0.3)	0.2	(2.8)	(1.4) (2.5)	0.3	(3.3)
Proceeds on disposal of property, plant and equipment	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Purchase of investment property	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Proceeds on disposal of investment property	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Purchase of intangible assets	(0.0)	0.0	(0.2)	(0.2)	0.0	(0.2)	(0.2)	0.0
Proceeds on disposal of intangible assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Expenditure on capitalised development	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase/(decrease) in Capital Creditors	(0.4)	0.0	0.3	0.3	0.0	0.3	0.3	0.0
Payments for other capitalised costs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Purchase of subsidiaries net of cash acquired	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net bank balance acquired with subsidiaries	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Proceeds from disposal of subsidiaries net of cash disposed	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net bank balance disposed with subsidiaries	0.0	0.0	0.0	0.0	0.0	0.0 0.0	0.0	0.0
Purchase of associates net of cash acquired Net bank balance acquired with associates	0.0 0.0	0.0	0.0	0.0	0.0 0.0	0.0	0.0 0.0	0.0 0.0
Proceeds from disposal of associates net of cash disposed	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net bank balance disposed with associates	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Purchase of joint ventures net of cash acquired	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net bank balance acquired with associates	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Proceeds from disposal of joint ventures net of cash disposed	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net bank balance disposed with joint venture	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Government grants received	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deposits and investments made	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deposits and investments liquidated	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other cash flows from investing activities	(5.7)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cashflow before financing	3.6	(3.5)	(10.9)	(7.4)	0.3	(3.3)	(3.6)	(4.2)
Cashflow from financing activities	7.1	3.0 0.0	15.1 12.0	12.1 12.0	19.1 15.0	15.0 12.0	(4.1)	19.1 15.0
Public Dividend Capital received Public Dividend Capital repaid	7.1 0.0	0.0	0.0	0.0	15.U 0.0	0.0	0.0	0.0
Public Dividends capital repaid PDC Dividends paid	(4.9)	0.0	0.0	0.0	(2.8)	(2.9)	(O. 1)	(5.6)
Interest (paid) on bridging loans	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Interest (paid) on commercial loans	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Interest (paid) on non-commercial loans	(0.2)	(0.2)	(0.1)	0.1	(0.3)	(0.2)	0.1	(0.3)
Interest (paid) on overdraft and working capital facility	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Interest element of finance lease rental payments - other	(0.0)	0.0	(0.0)	(0.0)	0.0	(0.0)	(0.0)	0.0
Interest element of finance lease rental payments - On-balance sheet PFI	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital element of finance lease rental payments - other	(0.1)	0.0	(0.0)	(0.0)	0.0	(0.1)	(0.1)	0.0
Capital element of finance lease rental payments - On-balance sheet PFI	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Interest received on cash and cash equivalents	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.1
Movement in Other grants/Capital received	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Donations received in cash	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Drawdown of bridging loans	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Repayment of bridging loans Drawdown of non-commercial loans	0.0	0.0	0.0	0.0 0.1	0.0	0.0 6.7	0.0	0.0
Drawdown of non-commercial loans Repayment of non-commercial loans	0.0 (0.5)	3.4 (0.2)	3.5 (0.2)	0.1	7.6 (0.5)	6.7 (0.5)	(0.9) (0.0)	10.4 (0.5)
Drawdown of commercial loans	0.0	0.0	0.2)	0.0	0.5)	0.0	0.0	0.5)
Repayment of commercial loans	(0.0)	(O.O)	0.0	0.0	(0.0)	(0.0)	0.0	(0.0)
(Increase)/decrease in non-current receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase/(decrease) in non-current payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other cash flows from financing activities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net increase/(decrease) in cash	5.2	(0.5)	4.2	4.7	19.4	11.7	(7.6)	14.9
Cash at period end	12.8	32.1	24.5	(7.6)	32.1	24.5	(7.6)	27.7

	Previous YE	Current Quarter			YTD			FY
êm .	Actual	Plan	Actual	Variance	Plan	Actual	Variance	Plan
Community	0.0	0.5	(0.0)	(0.7)	4.0	0.0	(0.0)	0.0
Co Cost & volume contract revenue Co Block contract revenue	0.0 34.7	0.5 8.0	(0.2) 8.8	(0.7) 0.8	1.6 24.1	0.8 25.3	(0.8) 1.2	2.2 32.2
Ambulance	34.7	0.0	0.0	0.8	24.1	25.3	1.2	32.2
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Am Cost & volume contract revenue Am Block contract revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Am Other clinical MS revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Mental Health	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Mh Cost & volume contract revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Mh Block contract revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Mh Clinical partnership (s31) revenue Mh Secondary commissioning revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Mh Other clinical MS revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Acute	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Ac Elective revenue	57.5	16.6	17.3	0.8	48.2	49.6	1.4	64.5
Ac Non-Elective revenue	95.8	23.4	25.4	2.0	67.8	74.7	6.9	90.6
Ac Outpatient revenue	60.1	15.8	16.0	0.1	46.1	49.8	3.7	61.7
Ac A&E revenue	12.0	3.4	3.3	(0.0)	9.7	10.2	0.5	13.0
Ac other revenue	83.0	28.8	28.4	(0.4)	83.6	77.2	(6.5)	112.0
Private patient revenue	1.0	0.3	0.3	(0.0)	0.8	0.8	(0.0)	3.0
Grants and donations in cash	0.2	0.0	0.2	0.1	0.1	0.5	0.4	0.2
Other operating revenues	59.4	12.7	14.5	1.8	38.0	40.9	2.9	48.7
Total operating revenue for EBITDA	403.7	109.5	113.9	4.4	320.1	329.7	9.7	428.0
Grants and donations of PPE and intangible assets	0.5	0.1	0.0	(0.1)	0.4	0.0	(0.4)	0.5
Total operating revenue	404.2	109.6	113.9	4.3	320.4	329.7	9.3	428.4
Employee Expenses	(262.5)	(71.7)	(72.3)	(0.6)	(212.2)	(216.1)	(3.9)	(284.3)
Drugs expense	(30.5)	(7.8)	(8.9)	(1.1)	(23.0)	(25.8)	(2.8)	(30.8)
Supplies (clinical & non-clinical)	(46.8)	(13.1)	(13.6)	(0.5)	(38.7)	(39.6)	(0.9)	(51.9)
Clinical supplies	(40.4)	(11.4)	(11.6)	(0.2)	(33.6)	(33.9)	(0.3)	(45.1)
Non-clinical supplies	(6.4)	(1.7)	(2.0)	(0.3)	(5.1)	(5.7)	(0.5)	(6.9)
PFI expenses	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other expenses	(44.9)	(11.0)	(13.7)	(2.7)	(31.4)	(34.1)	(2.8)	(42.1)
Decrease (increase) in inventories of finished goods & WIP	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Vehicle Fuel costs (ambulance trusts)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cost of Secondary Commissioning of mandatory services	(3.3)	(1.2)	(0.8)	0.4	(3.5)	(2.2)	1.2	(4.6)
Research & Development expense	(4.4)	(1.2)	(1.2)	0.1	(3.7)	(3.3)	0.4	(4.9)
Education and training expense	(1.0)	(0.3)	(0.3)	(0.0)	(1.0)	(0.7)	0.3	(1.3)
Misc. other Operating expenses	(34.9)	(8.0)	(8.9)	(0.9)	(22.5)	(25.3)	(2.8)	(30.3)
otal operating expenses within EBITDA	(384.6)	(103.5)	(108.4)	(4.9)	(305.3)	(315.6)	(10.3)	(409.1)
TOTAL	40.4			(0.5)			(0.0)	40.0
EBITDA Depreciation and amortisation	19.1 (8.8)	5.9 (2.7)	5.5 (2.7)	(0.5) (0.0)	14.8 (8.1)	14.1 (8.1)	(0.6) (0.0)	18.9 (10.9)
Depreciation and Amortisation - owned assets	(8.6)	(2.7)	(2.7)	(0.0)	(8.1)	(8.1)	(0.0)	(10.9)
Depreciation and Amortisation - assets held under finance leases	(0.1)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Depreciation and Amortisation - PFI assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Impairments & Restructuring	(4.3)	0.0	(0.1)	(0.1)	0.0	(0.7)	(0.7)	(0.3)
Fotal operating expenses	(397.7)	(106.3)	(111.3)	(5.0)	(313.4)	(324.4)	(11.0)	(420.3)
Operating Surplus (Deficit)	6.5	3.3	2.6	(0.7)	7.0	5.3	(1.7)	8.2
Profit (loss) on asset disposal	0.0	0.0	0.0	0.0	0.0	(0.0)	(0.0)	0.0
Net interest	(0.1)	(0.1)	(0.0)	0.0	(0.1)	(0.1)	0.0	(0.2)
Taxation	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
PDC dividend	(5.0)	(1.4)	(1.4)	(0.0)	(4.2)	(4.2)	(0.0)	(5.6)
Other non-operating items	69.4	0.1	(0.1)	(0.2)	0.4	(0.1)	(0.4)	0.5
let Surplus / (Deficit)	70.4	1.9	1.1	(0.8)	2.7	1.0	(1.7)	2.4
EBITDA % of Op. revenue	4.7%	5.4%	4.8%	-0.6%	4.6%	4.3%	-0.3%	4.4%
EBITDA	19.1	5.9	5.5	(0.5)	14.8	14.1	(0.6)	18.9
Change in Current Receivables	(5.4)	(3.0)	(5.0)	(2.0)	2.0	3.1	1.1	(1.0)
(Increase)/decrease in tax receivable	0.0	0.0	0.2	0.2	0.0	0.1	0.1	0.0
(Increase)/decrease in NHS Trade Receivables	(4.0)	(3.0)	(5.0)	(2.0)	2.0	3.6	1.6	(1.0)
(Increase)/decrease in Non NHS Trade Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
(Increase)/decrease in other related party receivables	(0.8)	0.0	0.9	0.9	0.0	0.9	0.9	0.0
	(0.5)	0.0	(1.2)	(1.2)	0.0	(1.6)	(1.6)	0.0
(Increase)/decrease in other receivables	8.2	0.0			0.0	(2.4)	(2.4)	0.0
(Increase)/decrease in other receivables			(0.5)	(0.5)				0.0
(Increase)/decrease in other receivables Change in Current Payables				(0.5) 0.1	0.0	(0.2)	(0.2)	
(Increase)/decrease in other receivables Change in Current Payables Increase/(decrease) in tax payable	0.0	0.0	0.1	0.1	0.0 0.0	(0.2)	(0.2)	
(Increase)/decrease in other receivables Change in Current Payables				0.1 (0.5)	0.0 0.0 0.0	(0.2) (2.7) 0.5	(2.7) 0.5	0.0 0.0
(Increase)/decrease in other receivables Change in Current Payables Increase/(decrease) in tax payable Increase/(decrease) in Trade Creditors Increase/(decrease) in Other Creditors	0.0 4.4 3.8	0.0 0.0 0.0	0.1 (0.5) (0.0)	0.1 (0.5) (0.0)	0.0 0.0	(2.7) 0.5	(2.7) 0.5	0.0 0.0
(Increase)/decrease in other receivables Change in Current Payables Increase/(decrease) in tax payable Increase/(decrease) in Trade Creditors	0.0 4.4 3.8 (1.0)	0.0 0.0 0.0 0.0	0.1 (0.5) (0.0) (9.9)	0.1 (0.5) (0.0) (9.9)	0.0 0.0 (3.0)	(2.7) 0.5 (11.2)	(2.7) 0.5 (8.2)	0.0 0.0 0.0
(Increase)/decrease in other receivables Change in Current Payables Increase/decrease) in tax payable Increase/decrease) in Tade Creditors Increase/decrease) in Other Creditors Other changes in WC	0.0 4.4 3.8	0.0 0.0 0.0	0.1 (0.5) (0.0)	0.1 (0.5) (0.0)	0.0 0.0	(2.7) 0.5	(2.7) 0.5	0.0 0.0
(Increase)/decrease in other receivables Change in Current Payables Increase/(decrease) in Itax payable Increase/(decrease) in Trade Creditors Increase/(decrease) in Other Creditors Other changes in WC Change in Non Current Provisions Other non-cash items	0.0 4.4 3.8 (1.0) 0.4	0.0 0.0 0.0 0.0 0.0	0.1 (0.5) (0.0) (9.9) 0.0	0.1 (0.5) (0.0) (9.9) 0.0	0.0 0.0 (3.0) 0.0	(2.7) 0.5 (11.2) (0.0)	(2.7) 0.5 (8.2) (0.0)	0.0 0.0 0.0 0.0
(Increase)/decrease in other receivables Change in Current Payables Increase/(decrease) in Itax payable Increase/(decrease) in Trade Creditors Increase/(decrease) in Other Creditors Other changes in WC Change in Non Current Provisions Other non-cash items	0.0 4.4 3.8 (1.0) 0.4 (0.3)	0.0 0.0 0.0 0.0 0.0 0.0 0.2	0.1 (0.5) (0.0) (9.9) 0.0 2.3	0.1 (0.5) (0.0) (9.9) 0.0 2.1	0.0 0.0 (3.0) 0.0 0.2	(2.7) 0.5 (11.2) (0.0) 1.8	(2.7) 0.5 (8.2) (0.0) 1.5	0.0 0.0 0.0 0.0 0.0
(Increase)/decrease in other receivables Change in Current Payables Increase/(decrease) in Tax payable Increase/(decrease) in Trade Creditors Increase/(decrease) in Other Creditors Other changes in WC Change in Non Current Provisions Other non-cash items ashflow from operating activities Capital expenditure (accurals basis)	0.0 4.4 3.8 (1.0) 0.4 (0.3) 21.1	0.0 0.0 0.0 0.0 0.0 0.0 0.2 3.1	0.1 (0.5) (0.0) (9.9) 0.0 2.3	0.1 (0.5) (0.0) (9.9) 0.0 2.1 (10.7)	0.0 0.0 (3.0) 0.0 0.2 14.0	(2.7) 0.5 (11.2) (0.0) 1.8 5.3	(2.7) 0.5 (8.2) (0.0) 1.5 (8.6)	0.0 0.0 0.0 0.0 0.2 18.1
(Increase)/decrease in other receivables Change in Current Payables Increase/(decrease) in tax payable Increase/(decrease) in Trade Creditors Increase/(decrease) in Other Creditors Other changes in WC Change in Nan Current Provisions Other non-cash items asthfow from operating activities Capital expenditure (accurals basis) Asset sale proceeds	0.0 4.4 3.8 (1.0) 0.4 (0.3) 21.1	0.0 0.0 0.0 0.0 0.0 0.2 3.1 (6.6)	0.1 (0.5) (0.0) (9.9) 0.0 2.3 (7.6) (3.6)	0.1 (0.5) (0.0) (9.9) 0.0 2.1 (10.7) 3.0	0.0 0.0 (3.0) 0.0 0.2 14.0 (13.7)	(2.7) 0.5 (11.2) (0.0) 1.8 5.3 (8.9)	(2.7) 0.5 (8.2) (0.0) 1.5 (8.6) 4.8	0.0 0.0 0.0 0.0 0.2 18.1 (22.3)
(Increase)/decrease in other receivables Change in Current Payables Increase/(decrease) in tax payable Increase/(decrease) in Trade Creditors Increase/(decrease) in Other Creditors Other changes in WC Change in Non Current Provisions Other non-cash items ashflow from operating activities Capital expenditure (accurals basis) Asset sale proceeds dither Investing cash flows	0.0 4.4 3.8 (1.0) 0.4 (0.3) 21.1 0.0 0.1	0.0 0.0 0.0 0.0 0.0 0.0 0.2 3.1 (6.6) 0.0	0.1 (0.5) (0.0) (9.9) 0.0 2.3 (7.6) (3.6) 0.0	0.1 (0.5) (0.0) (9.9) 0.0 2.1 (10.7) 3.0 0.0	0.0 0.0 (3.0) 0.0 0.2 14.0 (13.7) 0.0	(2.7) 0.5 (11.2) (0.0) 1.8 5.3 (8.9) 0.0	(2.7) 0.5 (8.2) (0.0) 1.5 (8.6) 4.8 0.0	0.0 0.0 0.0 0.0 0.2 18.1 (22.3) 0.0
(Increase)/decrease in other receivables Change in Current Payables Increase/(decrease) in tax payable Increase/(decrease) in Trade Creditors Increase/(decrease) in Trade Creditors Other changes in WC Change in Non Current Provisions Other non-cash items ashflow from operating activities Capital expenditure (accurals basis) Asset sale proceeds other Investing cash flows	0.0 4.4 3.8 (1.0) 0.4 (0.3) 21.1 0.0 0.1 (17.5)	0.0 0.0 0.0 0.0 0.0 0.0 0.2 3.1 (6.6) 0.0	0.1 (0.5) (0.0) (9.9) 0.0 2.3 (7.6) (3.6) 0.0 0.3	0.1 (0.5) (0.0) (9.9) 0.0 2.1 (10.7) 3.0 0.0 0.3	0.0 0.0 (3.0) 0.0 0.2 14.0 (13.7) 0.0	(2.7) 0.5 (11.2) (0.0) 1.8 5.3 (8.9) 0.0 0.3	(2.7) 0.5 (8.2) (0.0) 1.5 (8.6) 4.8 0.0 0.3	0.0 0.0 0.0 0.0 0.2 18.1 (22.3) 0.0
(Increase)/decrease in other receivables Change in Current Payables Increase/decrease) in tax payable Increase/decrease) in Tade Oretifors Increase/decrease) in Tother Creditors Other changes in WC Change in Non Current Provisions Other non-cash items astifow from operating activities Capital expenditure (accurals basis) Asset sale proceeds other Innesting cash flows astiflow brom certains astiflow from coredity astiflow from certains astiflow from certains astiflow from certains astiflow form certains astiflow form certains astiflow form certains astiflow before financing	0.0 4.4 3.8 (1.0) 0.4 (0.3) 21.1 0.0 0.1 (17.5) 3.6	0.0 0.0 0.0 0.0 0.0 0.2 3.1 (6.6) 0.0 0.0 (3.5)	0.1 (0.5) (0.0) (9.9) 0.0 2.3 (7.6) (3.6) 0.0 0.3	0.1 (0.5) (0.0) (9.9) 0.0 2.1 (10.7) 3.0 0.0 0.3 (7.4)	0.0 0.0 (3.0) 0.0 0.2 14.0 (13.7) 0.0 0.0 0.3	(2.7) 0.5 (11.2) (0.0) 1.8 5.3 (8.9) 0.0 0.3 (3.3)	(2.7) 0.5 (8.2) (0.0) 1.5 (8.6) 4.8 0.0 0.3 (3.6)	0.0 0.0 0.0 0.0 0.2 18.1 (22.3) 0.0 0.0 (4.2)
(Increase)/decrease in other receivables Change in Current Payables Increase/(decrease) in tax payable Increase/(decrease) in Trade Creditors Increase/(decrease) in Trade Creditors Cherchanges in WC Change in Non Current Provisions Other non-cash items ashflow from operating activities Capital expenditure (accurals basis) Asset sale proceeds other investing cash flows ashflow before financing Net interest (paid) on bridging loans Interest (paid) on bridging loans Interest (paid) on commercial loans	0.0 4.4 3.8 (1.0) 0.4 (0.3) 21.1 0.0 0.1 (17.5) 3.6 (0.2)	0.0 0.0 0.0 0.0 0.0 0.0 0.2 3.1 (6.6) 0.0 0.0 0.0 (3.5) (0.2)	0.1 (0.5) (0.0) (9.9) 0.0 2.3 (7.6) (3.6) 0.0 0.3 (10.9) (0.1)	0.1 (0.5) (0.0) (9.9) 0.0 2.1 (10.7) 3.0 0.0 0.3 (7.4)	0.0 0.0 (3.0) 0.0 0.2 14.0 (13.7) 0.0 0.0 0.3 (0.3)	(2.7) 0.5 (11.2) (0.0) 1.8 5.3 (8.9) 0.0 0.3 (3.3) (0.2)	(2.7) 0.5 (8.2) (0.0) 1.5 (8.6) 4.8 0.0 0.3 (3.6) 0.1	0.0 0.0 0.0 0.2 18.1 (22.3) 0.0 0.0 (4.2) (0.3)
(Increase)/decrease in other receivables Change in Current Payables Increase/(decrease) in tax payable Increase/(decrease) in Tade Creditors Increase/(decrease) in Other Creditors Other changes in WC Change in Non Current Provisions Other non-eash items astiflow from operating activities Capital expenditure (accurals basis) Asset sale proceeds other Investing cash flows astiflow serior of financing Net interest Interest (paid) on bridging loans	0.0 4.4 3.8 (1.0) 0.4 (0.3) 21.1 0.0 0.1 (17.5) 3.6 (0.2)	0.0 0.0 0.0 0.0 0.0 0.2 3.1 (6.6) 0.0 0.0 (3.5) (0.2) 0.0	0.1 (0.5) (0.0) (9.9) 0.0 2.3 (7.6) (3.6) 0.0 0.3 (10.9) (0.1)	0.1 (0.5) (0.0) (9.9) 0.0 2.1 (10.7) 3.0 0.0 0.3 (7.4) 0.1	0.0 0.0 (3.0) 0.0 0.2 14.0 (13.7) 0.0 0.0 0.3 (0.3)	(2.7) 0.5 (11.2) (0.0) 1.8 5.3 (8.9) 0.0 0.3 (3.3) (0.2)	(2.7) 0.5 (8.2) (0.0) 1.5 (8.6) 4.8 0.0 0.3 (3.6) 0.1	0.0 0.0 0.0 0.0 0.2 18.1 (22.3) 0.0 0.0 (4.2) (0.3)
(Increase)/decrease in other receivables Change in Current Payables Increase/(decrease) in tax payable Increase/(decrease) in Trade Creditors Increase/(decrease) in Trade Creditors Cher changes in Not Sashflow from operating activities Capital expenditure (accurals basis) Asset sale proceeds cother investing cash flows ashflow before financing Net interest (paid) on bridging loans Interest (paid) on commercial loans Interest (paid) on non-commercial loans Interest (paid) on bank overdatats	0.0 4.4 3.8 (1.0) 0.4 (0.3) 21.1 0.0 0.1 (17.5) 3.6 (0.2) 0.0 0.0	00 00 00 00 00 00 02 3.1 (6.6) 00 00 0.35) (0.2) 0.0	0.1 (0.5) (0.0) (9.9) 0.0 2.3 (7.6) (3.6) 0.0 0.3 (10.9) (0.1) 0.0 0.0	0.1 (0.5) (0.0) (9.9) 0.0 2.1 (10.7) 3.0 0.0 0.3 (7.4) 0.1	0.0 0.0 (3.0) 0.2 14.0 (13.7) 0.0 0.0 0.3 (0.3) 0.0	(2.7) 0.5 (11.2) (0.0) 1.8 5.3 (8.9) 0.0 0.3 (3.3) (0.2) 0.0	(2.7) 0.5 (8.2) (0.0) 1.5 (8.6) 4.8 0.0 0.3 (3.6) 0.1	0.0 0.0 0.0 0.0 0.2 18.1 (22.3) 0.0 0.0 (4.2) (0.3) 0.0
(Increase)/decrease in other receivables Change in Current Payables Increase/decrease) in tax payable Increase/decrease) in Tade Oreditors Increase/decrease) in Other Creditors Other changes in WC Change in Non Current Provisions Other non-cash items astflow from operating activities Capital expenditure (accurals basis) Asset sale proceeds other Investing cash flows astflow by Competing astivities Interest (paid) on bridging loans Interest (paid) on bridging loans Interest (paid) on nor-commercial loans Interest (paid) on nor-commercial loans Interest (paid) on nor-commercial loans	0.0 4.4 3.8 (1.0) 0.4 (0.3) 21.1 0.0 0.1 (17.5) 3.6 (0.2) 0.0 (0.2) 0.0	00 00 00 00 00 00 02 3.1 (6.5) 0.0 0.0 (3.5) (0.2) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	0.1 (0.5) (0.0) (9.9) (0.0) (9.9) (0.0) (2.3 (7.6) (3.6) (0.0) (3.6) (0.1) (0.1) (0.0) (0.1)	0.1 (0.5) (0.0) (9.9) 0.0 2.1 (10.7) 3.0 0.0 0.3 (7.4) 0.1	0.0 0.0 (3.0) 0.0 0.2 14.0 (13.7) 0.0 0.0 0.3 (0.3) 0.0 0.0 0.3	(2.7) 0.5 (11.2) (0.0) 1.8 5.3 (6.9) 0.0 0.3 (3.3) (0.2) 0.0 (0.2)	(2.7) 0.5 (8.2) (0.0) 1.5 (8.6) 4.8 0.0 0.3 (3.6) 0.1 0.0 0.0	0.0 0.0 0.0 0.0 0.2 18.1 (22.3) 0.0 (4.2) (0.3) 0.0 (0.3)
(Increase)/decrease in other receivables Change in Current Payables Increase/(decrease) in Tarde Creditors Increase/(decrease) in Trade Creditors Increase/(decrease) in Trade Creditors Cher changes in NC Cher changes in NC Change in No. Current Provisions Cher non-cash items ashflow from operating activities Capital expenditure (accurals basis) Asset sale proceeds other Investing cash flows ashflow from financing Net interest (paid) on bridging loans Interest (paid) on commercial loans Interest (paid) on non-commercial loans Interest (paid) on bank overdrafts Interest element of finance lease rental payments - On-balance sheet PFI Interest Interest of Interest of lease ear ental payments - On-balance sheet PFI Interest Interest of Interest of lease ear ental payments - On-balance sheet PFI	0.0 4.4 3.8 (1.0) 0.4 (0.3) 21.1 0.0 0.1 (17.5) 3.6 (0.2) 0.0 (0.2)	00 00 00 00 00 00 02 3.1 (6.6) 00 00 00 (3.5) (0.2) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	0.1 (0.5) (0.0) (9.9) (0.0) (9.9) (0.0) (2.3) (7.6) (3.6) (0.0) (3.6) (0.1) (0.1) (0.0) (0.1) (0.0) (0.1) (0.0)	0.1 (0.5) (0.0) (9.9) 0.0 2.1 (10.7) 3.0 0.0 0.3 (7.4) 0.1	0.0 0.0 (3.0) 0.0 0.2 14.0 (13.7) 0.0 0.0 0.3 (0.3) 0.0 0.0 0.0	(2. 7) 0.5 (11.2) (0.0) 1.8 5.3 (8.9) 0.0 0.3 (3.3) (0.2) 0.0 0.0 0.0 0.0	(2.7) 0.5 (8.2) (0.0) 1.5 (8.6) 4.8 0.0 0.3 (3.6) 0.1 0.0 0.0	0.0 0.0 0.0 0.0 0.2 18.1 (22.3) 0.0 (4.2) (0.3) 0.0 (0.3)
(Increase)/decrease in other receivables Chango in Current Psyables Increase/decrease) in tax payable Increase/decrease) in Tade Creditors Increase/decrease) in Tode Creditors Other changes in WC Change in Non Current Provisions Other non-cash items astrition from operating activities Capital expenditure (accurals basis) Asset sale proceeds other Investing cash flows astrition from Creditorian (accurate basis) Net interest Interest (paid) on bridging loans Interest (paid) on commercial loans Interest (paid) on non-commercial loans Interest (paid) on hon-depression loans Interest (paid) on hon-depres	0.0 4.4 3.8 (1.0) 0.4 (0.3) 21.1 0.0 0.1 (17.5) 3.6 (0.2) 0.0 (0.2) 0.0 (0.2)	00 00 00 00 00 00 00 02 3.1 (6.5) 0.0 0.0 (0.2) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	0. f (0.5) (0.0) (0.1 (0.5) (0.0) (9.9) 0.0 2.1 (10.7) 3.0 0.0 0.3 (7.4) 0.1 0.0 0.1 0.0 0.1	0.0 (3.0) 0.0 0.2 14.0 (13.7) 0.0 0.3 (0.3) 0.0 0.0 (0.3) 0.0	(2.7) 0.5 (11.2) (0.0) 1.8 5.3 (8.9) 0.0 0.3 (3.3) (0.2) 0.0 (0.2) 0.0 (0.2)	(2.7) 0.5 (8.2) (0.0) 1.5 (8.6) 4.8 0.0 0.3 (3.6) 0.1 0.0 0.1 0.0 0.1	0.0 0.0 0.0 0.0 0.2 18.1 (22.3) 0.0 0.0 (4.2) (0.3) 0.0 (0.3) 0.0
(Increase)/decrease in other receivables Change in Current Psyables Increase/(decrease) in tax payable Increase/(decrease) in Trade Creditors Increase/(decrease) in Trade Creditors Other changes in NC Change in NO Current Provisions Other non-cash items asaftlow from operating activities Capital expenditure (accurals basis) Asset sale proceeds other Investing cash flows asaftlow from Cerease in Commercial Commercial Interest (paid) on bridging Ioans Interest (paid) on commercial Ioans Interest (paid) on non-commercial Ioans Interest (paid) on bridging Ioans Io	0.0 4.4 3.8 (1.0) 0.4 (0.3) 21.1 0.0 0.1 (17.5) 3.6 (0.2) 0.0 (0.2) 0.0 (0.0) (4.9)	00 00 00 00 00 00 02 3.1 (6.6) 00 00 00 (3.5) (0.2) 00 00 00 00 00 00 00 00 00 00 00 00 00	0. f (0.5) (0.0) (9.9) 0.0 2.3 (7.6) (3.6) 0.0 0.3 (10.9) (0.1) 0.0 (0.1) 0.0 (0.0) (0.0) (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 0.0 (0.0) 0.0 0.0 0.0 0.0 (0.0) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	0.1 (0.5) (0.0) (9.9) 0.0 2.1 (10.7) 3.0 0.0 0.3 (7.4) 0.1 0.0 0.1 0.0 0.1 0.0	0.0 (3.0) 0.0 0.2 14.0 (13.7) 0.0 0.3 (0.3) 0.0 0.0 0.0 0.0 0.0	(2.7) 0.5 (11.2) (0.0) 1.8 5.3 (8.9) 0.0 0.3 (3.3) (0.2) 0.0 (0.2) 0.0 (0.2)	(2.7) 0.5 (8.2) (0.0) 1.5 (8.6) 4.8 0.0 0.3 (3.6) 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0	0.0 0.0 0.0 0.0 0.2 18.1 (22.3) 0.0 (4.2) (0.3) 0.0 (0.3) 0.0 (0.3) 0.0 (0.3)
(Increase)/decrease in other receivables Change in Current Payables Increase/(decrease) in Tande Creditors Increase/(decrease) in Tande Creditors Increase/(decrease) in Tande Creditors Other changes in NC Change in NC Change in NC Change in No Current Provisions Other non-cash items ashflow from operating activities Capital expenditure (accurals basis) Asset sale proceeds other Investing cash flows ashflow by Company (ash flows) Interest (paid) on bridging loans Interest (paid) on bridging loans Interest (paid) on commercial loans Interest (paid) on bank overdrafts Interest element of finance lease eratal payments - other Interest element of finance lease rental payments - On-balance sheet PFI PDC dividends (paid) Movement in loans	0.0 4.4 3.8 (1.0) 0.4 (0.3) 21.1 0.0 0.1 (17.5 3.6 (0.2) 0.0 (0.2) 0.0 (0.2) 0.0 (0.2) 0.0 (0.2) 0.0 (0.2) 0.0 (0.2)	00 00 00 00 00 00 00 00 3.1 (6.6) 00 00 (3.5) (0.2) 00 00 00 00 00 00 00 00 00 00 00 00 00	0.1 (0.5) (0.0) (9.9) 0.0 2.3 (7.6) (3.6) 0.0 0.3 (10.9) (0.1) 0.0 (0.1) 0.0 (0.0) 0.0 0.0 0.0 0.0 0.0	0.1 (0.5) (0.0) (9.9) 0.0 2.1 (10.7) 3.0 0.0 0.3 (7.4) 0.1 0.0 0.0 0.1 (0.0) 0.0 0.0	0.0 (3.0) 0.0 0.2 14.0 (13.7) 0.0 0.3 (0.3) 0.0 (0.3) 0.0 (0.3) 0.0 (0.3) 0.0 (0.3)	(2.7) 0.5 (11.2) (0.0) 1.8 5.3 (8.9) 0.0 0.3 (0.2) 0.0 (0.2) 0.0 (0.2) 0.0 (0.2) 0.0 (0.2) 0.0 0.0 (0.2) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	(2. 7) 0.5 (8. 2) (0. 0) 1.5 (8. 6) 4. 8 0. 0 0. 3 (3. 6) 0. 1 0. 0 0. 0	0.0 0.0 0.0 0.2 18.1 (22.3) 0.0 (4.2) (0.3) 0.0 (0.3) 0.0 (0.3) 0.0 (5.6) 9.9
(Increase)/decrease in other receivables Change in Current Payables Increase/(decrease) in tax payable Increase/(decrease) in Trade Creditors Increase/(decrease) in Trade Creditors Increase/(decrease) in Trade Creditors Other changes in WC Change in Non Current Provisions Other non-cash items ashflow from operating activities Capital expenditure (accurals basis) Asset sale proceeds other investing cash flows ashflow before financing Not interest (paid) on bridging loans Interest (paid) on commercial loans Interest (paid) on commercial loans Interest (paid) on band contentatis Interest delign on band contentatis Interest element of finance lease rental payments - other Interest element of finance lease rental payments - On-balance sheet PFI PDC dividends (paid) Movement in loans PDC received((repaid)	0.0 4.4 3.8 (1.0) 0.4 (0.3) 21.1 21.1 0.0 0.1 (17.5) 3.6 (0.2) 0.0 (0.2) 0.0 (0.2) 0.0 (0.0) (0.0) (0.5) 7.1	00 00 00 00 00 00 02 3.1 (6.6) 00 00 00 00 02 00 00 00 00 00 00 00 00	0.1 (0.5) (0.0) (9.8) (0.0) (9.8) (0.0) (9.8) (0.0) (0.0) (0.1) (0.0) (0.1) (0.0) (0	0.1 (0.5) (0.0) (9.9) 0.0 2.1 (10.7) 3.0 0.0 0.3 (7.4) 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	0.0 (3.0) 0.0 0.2 14.0 (13.7) 0.0 0.3 (0.3) 0.0 (0.3) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	(2.7) (0.5) (11.2) (0.0) 1.8 5.3 (8.9) 0.0 0.3 (3.3) (0.2) 0.0 (0.2) 0.0 (0.2) 0.0 (2.9) 6.1 12.0	(2. 7) (3. 5) (8. 2) (0. 0) 1.5 (8. 6) 4. 8 0. 0 0. 3 (3. 6) 0. 1 0. 0 0. 0 0. 1 0. 0 0. 0 0	0.0 0.0 0.0 0.0 0.2 18.1 (22.3) 0.0 0.0 (4.2) (0.3) 0.0 0.0 (0.3) 0.0 0.0 (5.6) 9.9
(Increase)/decrease in other receivables Change in Current Psyables Increase/(decrease) in Tarde Creditors Increase/(decrease) in Tarde Creditors Increase/(decrease) in Tarde Creditors Other Changes in NC Change i	0.0 4.4 3.8 (1.0) 0.4 (0.3) 21.1 0.0 0.1 (17.5 3.6 (0.2) 0.0 (0.2) 0.0 (0.2) 0.0 (0.2) 0.0 (0.2) 0.0 (0.2) 0.0 (0.2)	00 00 00 00 00 00 00 00 3.1 (6.6) 00 00 (3.5) (0.2) 00 00 00 00 00 00 00 00 00 00 00 00 00	0.1 (0.5) (0.0) (9.9) 0.0 2.3 (7.6) (3.6) 0.0 0.3 (10.9) (0.1) 0.0 (0.1) 0.0 (0.0) 0.0 0.0 0.0 0.0 0.0	0.1 (0.5) (0.0) (9.9) 0.0 2.1 (10.7) 3.0 0.0 0.3 (7.4) 0.1 0.0 0.0 0.1 (0.0) 0.0 0.0	0.0 0.0 0.0 0.0 0.2 14.0 (13.7) 0.0 0.3 (0.3) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	(2.7) 0.5 (11.2) (0.0) 1.8 5.3 (8.9) 0.0 0.3 (0.2) 0.0 (0.2) 0.0 (0.2) 0.0 (0.2) 0.0 (0.2) 0.0 0.0 (0.2) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	(2. 7) 0.5 (8. 2) (0. 0) 1.5 (8. 6) 4. 8 0. 0 0. 3 (3. 6) 0. 1 0. 0 0. 0	0.0 0.0 0.0 0.2 18.1 (22.3) 0.0 (4.2) (0.3) 0.0 (0.3) 0.0 (0.3) 0.0 (5.6) 9.9
(Increase)/decrease in other receivables Change in Current Psyables Increase/(decrease) in tax payable Increase/(decrease) in Trade Creditors Increase/(decrease) in Trade Creditors Change in Non Current Provisions Other non-cash items ashflow from operating activities Capital expenditure (accurals basis) Asset sale proceeds other investing cash flows ashflow from form of the control of the con	0.0 4.4 3.8 (1.0) 0.4 (0.3) 21.1 0.0 0.1 (17.5) 3.6 (0.2) 0.0 (0.2) 0.0 (0.2) 0.0 (0.2) 0.0 (0.2) 0.0 (0.5) 7.1	00 00 00 00 00 00 02 3.1 (6.6) 00 00 (3.5) (0.2) 00 00 00 00 00 00 00 00 00 00 00 00 00	0.1 (0.5) (0.0) (0	0.1 (0.5) (0.0) (9.9) 0.0 2.1 (10.7) 3.0 0.0 0.3 (7.4) 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0	0.0 0.0 (3.0) 0.0 0.2 14.0 (13.7) 0.0 0.0 0.3 (0.3) 0.0 0.0 (0.3) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	(2.7) (0.5) (11.2) (0.0) 1.8 5.3 (8.9) 0.0 0.3 (3.3) (0.2) 0.0 (0.2) 0.0 (0.2) 0.0 (0.2) 0.0 (0.2) 0.0 (0.0) 0.0 (0.0) 0.0 0.0 0.0 0.0 0.0 0.0 0.0	(2. 7) 0. 5 (8. 2) (0. 0) 1. 5 (8. 6) 4. 8 0. 0 0. 3 (3. 6) 0. 1 0. 0 0.	0.0 0.0 0.0 0.0 0.2 18.1 (22.3) 0.0 0.0 (4.2) (0.3) 0.0 0.0 (0.3) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.
(Increase)/decrease in other receivables Change in Current Payables Increase/(decrease) in tax payable Increase/(decrease) in Trade Creditors Increase/(decrease) in Trade Creditors Other changes in WC Change in Non Current Provisions Other non-cash items ashflow from operating activities Capital expenditure (accurals basis) Asset sale proceeds other Investing cash flows ashflow before financing Net interest (paid) on bridging loans Interest (paid) on commercial loans Interest (paid) on commercial loans Interest (paid) on hor-commercial loans Interest element of finance lease rental payments - other Interest element of finance lease rental payments - On-balance sheet PFI PDC dividends (paid) Movement in loans PDC received/(repaid) Donations received in cash other financing cashflows	0.0 4.4 3.8 (1.0) 0.4 (0.3) 21.1 0.0 0.1 (17.5) 3.6 (0.2) 0.0 (0.2) 0.0 (0.2) 0.0 (0.0) 0.0 (4.9) (0.5) 7.1	00 00 00 00 00 00 02 3.1 (6.6) 00 00 00 (0.2) 00 00 00 00 00 00 00 00 00 00 00 00 00	0.1 (0.5) (0.0) (0.5) (0.0) (0.0) (0.0) (0.1) (0.0) (0	0.1 (0.5) (0.0) (9.9) 0.0 2.1 (10.7) 3.0 0.0 0.3 (7.4) 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	0.0 0.0 0.0 0.0 0.2 14.0 (13.7) 0.0 0.3 0.0 0.3 0.0 0.0 0.0 0.0	(2.7) (0.5) (11.2) (0.0) 1.8 5.3 (8.9) 0.0 0.3 (0.2) 0.0 (0.2) 0.0 (0.2) 0.0 (0.2) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	(2. 7) (5. 5) (8. 2) (0. 0) 1. 5 (8. 6) 4. 8 0. 0 0. 3 (3. 6) 0. 1 0. 0 0. 0 0. 1 0. 0 0. 0 0. 1 0. 0 0. 0	0.0 0.0 0.0 0.0 0.1 18.1 (22.3) 0.0 0.0 (4.2) (0.3) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.

Worksheet "CoSRR"

Continuity of Service Shadow Risk Ratings (pilot indicators for 2013/14)

	Capital Se	rvice Cover	
IS04400 IS04100		PDC dividend expense Interest Expense on Overdrafts and Working Capital Facilities	from SoCI from SoCI
IS04110		Interest Expense on Bridging loans	from SoCI
IS04120		Interest Expense on Non-commercial borrowings	from SoCI
IS04130		Interest Expense on Commercial borrowings	from SoCI
IS04140		Interest Expense on Finance leases (non-PFI)	from SoCI
IS04150		Interest Expense on PFI leases & liabilities	from SoCI
IS04200		Other Finance Costs	from SoCI
IS04610		Non-Operating PFI costs (eg contingent rent)	from SoCI
CF07150		Public Dividend Capital repaid	from SoCF
CF07610		Repayment of bridging loans	from SoCF
CF07710		Repayment of non-commercial loans	from SoCF
CF07810		Repayment of commercial loans	from SoCF
CF07360		Capital element of finance lease rental payments - On-balance sheet PFI	from SoCF
CF07350		Capital element of finance lease rental payments - other	from SoCF
MEM0180	Amended Amended	Revenue available for Debt Service Capital Service Coper and Copital Service Cover metric	
	Amended	Capital Service Cover rating	
	Liquidity		
IS02000		Cash for CoS liquidity purposes Operating Expenses within EBITDA, Total Liquidity metric Liquidity rating	from SoFP from SoCI
		Continuity of Service Risk Rating	

Historic Year to 31-Mar-13	Reported Quarter to 30-Jun-13	Reported YTD to 30-Jun-13	Reported Quarter to 30-Sep-13	Reported YTD to 30-Sep-13	Reported Quarter to 31-Dec-13	Reported YTD to 31-Dec-13	Reported Quarter to 31-Mar-14	Reported YTD to 31-Mar-1
(5.005)	(1.391)	(1.391)	(1.392)	(2.783)	(1.392)	(4.175)		(4.175)
			-					
(0.210)	(0.053)	(0.053)	(0.051)	(0.104)	(0.066)	(0.170)	-	(0.170)
- 1		- '					-	
(0.021)	-	-	-	-	-	-	-	-
(0.035)					(0.081)	(0.081)		(0.081)
(0.035)					(0.061)	(0.061)		(0.061)
-	-	-	-	-			-	-
-	-	-	-	-	-	-	-	-
(0.493)	(0.248)	(0.248)		(0.248)	(0.247)	(0.495)	-	(0.495)
(0.024)			(0.019)	(0.019)		(0.019)	-	(0.019)
(0.107)	(0.050)	(0.050)		(0.050)	(0.030)	(0.080)		(0.080)
19.307	4.527	4.527	4.151	8.678	5.503	14.181	0.000	14.181
-5.895	-1.742	-1.742	-1.462	-3.204	-1.816	-5.020	0.000	-5.020
3.28x	2.60x	2.60x	2.84x	2.71x	3.03x	2.82x	0.00x	2.82x
4	4	4	4	4	4	4	1	4
0.339	2.541	2.541	2.947	2.947	18.188	18.188	0.000	0.000
-384.602 0.3	-102.579 2.2	-102.579 2.2	-104.618 2.5	-207.197 2.6	-108.444 15.1	-315.641 15.6	0.000	-315.641 0.0
	4							
4	4	4	4	4	4	4	4	4

key to scoring

Capital S	rvice Cov	50%	
4	3	2	1
2.5	1.75	1.25	<1.25

key to scoring

Liquidity		50%	
4	3	2	1
0	-7	-14	<-14
	Liquidity 4 0	4 3	4 3 2

Worksheet "Targets and Indicators"

Declaration of risks against healthcare targets and indicators for 2013-14	by York Te	eaching Ho	ospital												
These targets and indicators are set out in the Risk Assessment Framework Definitions can be found in Appendix A of the Risk Assessment Framework NOTE: If a particular indicator does not apply to your FT then please enter "Not relevant" for those lines	Key	Scoring	scoring	must complete may need to complete	Scoring	Quarter 1 Actual		aconing under	Quarter 2 Actual		Scoring under	Quarter 3 Actual			acoring under
Target or Indicator (per Risk Assessment Framework)	Threshold or target YTD	Compliance	Risk Assessment Framework	Risk declared at Annual Plan	Compliance	Performance	Achieved/Not Met	Compliance Framework	Performance	Achieved/Not Met	Compliance Framework	Performance	Achieved/Not Met	Any comments or explanations	Risk Assessme Framework
Referral to treatment time, 18 weeks in aggregate, admitted patients	90%	1.0	1.0	No	Trainemon	90.17%	Achieved	T Tullion on the	90.41%	Achieved	T Tallicwork	90.8%	Achieved	Any comments of explanations	T Tullie WOTK
Referral to treatment time, 18 weeks in aggregate, non-admitted patients	95%	1.0	1.0	No		95.40%	Achieved	-	95.34%	Achieved		95.7%	Achieved		
Referral to treatment time, 18 weeks in aggregate, incomplete pathways	92%	1.0	1.0	No	0	92.01%	Achieved	0	91.50%	Not met	1	92.0%	Achieved	*	0
A&E Clinical Quality- Total Time in A&E under 4 hours	95%	1.0	1.0	No	0	96.28%	Achieved	0	94.05%	Not met	1	93.4%	Not met		1
Cancer 62 Day Waits for first treatment (from urgent GP referral)	85%	1.0	1.0	No		0.00%	Achieved		89.40%	Achieved		0.0%	Achieved	The Trust believes this target has been achieved. Final performance will not be	
Cancer 62 Day Waits for first treatment (from NHS Cancer Screening Service referral)	90%	1.0	1.0	No	0	0.00%	Achieved	0	90.50%	Achieved	0	0.0%	Achieved	The Trust believes this target has been achieved. Final performance will not be	0
Cancer 31 day wait for second or subsequent treatment - surgery	94%	1.0	1.0	No		0.00%	Achieved		97.80%	Achieved		0.0%	Achieved	The Trust believes this target has been achieved. Final performance will not be	
Cancer 31 day wait for second or subsequent treatment - drug treatments	98%	1.0	1.0	No		0.00%	Achieved	-	99.50%	Achieved		0.0%	Achieved	The Trust believes this target has been achieved. Final performance will not be	
Cancer 31 day wait for second or subsequent treatment - radiotherapy	94%	1.0	1.0	No	0	0.00%	Not relevant	- 0	0.00%	Not relevant	0	0.0%	Not relevant	activeved. Pinal performance will not be	_
Cancer 31 day wait from diagnosis to first treatment	96%	0.5	1.0	No	0	0.00%	Achieved	0	99.30%	Achieved	0	0.0%	Achieved	The Trust believes this target has been	0
Cancer 2 week (all cancers)	93%	0.5	1.0	No		0.00%	Achieved		94.10%	Achieved		0.0%	Achieved	achieved. Final performance will not be The Trust believes this target has been	
Cancer 2 week (breast symptoms)	93%	0.5	1.0	No	0	0.00%	Achieved	0	93.10%	Achieved	-	0.0%	Not met	achieved. Final performance will not be The Trust believes there is a risk to delivery of	
Care Programme Approach (CPA) follow up within 7 days of discharge	95%	1.0	1.0	No	- 0	0.00%	Not relevant	- 0	0.00%	Not relevant	0	0.0%	Not relevant	this target. Final performance data will not be	-
Care Programme Approach (CPA) formal review within 12 months	95%	1.0	1.0	No	0	0.00%	Not relevant	0	0.00%	Not relevant		0.0%	Not relevant	-	0
Admissions had access to crisis resolution / home treatment teams	95%	1.0	1.0	No	0	0.00%	Not relevant	0	0.00%	Not relevant	0	0.0%	Not relevant	-	0
Meeting commitment to serve new psychosis cases by early intervention teams	95%	0.5	1.0	No	0	0.00%	Not relevant	0	0.00%	Not relevant	0	0.0%	Not relevant	•	0
Ambulance Category A 8 Minute Response Time - Red 1 Calls	75%	0.5	1.0	No		0.00%	Not relevant	- 0	0.00%	Not relevant		0.0%	Not relevant	•	0
Ambulance Category A 8 Minute Response Time - Red 2 Calls	75%	0.5	1.0	No	0	0.00%	Not relevant	- 0	0.00%	Not relevant	0	0.0%	Not relevant		0
Ambulance Category A 19 Minute Transportation Time	95%	1.0	1.0	No	0	0.00%	Not relevant	0	0.00%	Not relevant	0	0.0%	Not relevant		0
Clostridium Difficile -meeting the C.Diff objective	32	1.0	1.0	No	0	21	Not met	1	33	Not met	1	54	Not met		1
MRSA - meeting the MRSA objective	0	1.0	N/A	No	0	1	Achieved	0	2	Achieved	0	N/A	Not relevant	No longer applicable under RAF	
Minimising MH delayed transfers of care	<=7.5%	1.0	1.0	No.	0	0.00%	Not relevant	0	0.00%	Not relevant	0	0.0%	Not relevant	To longer applicable direct for	0
Data completeness, MH: identifiers	97%	0.5	1.0	No	0	0.00%	Not relevant	0	0.00%	Not relevant	0	0.0%	Not relevant	-	0
Data completeness, MH: automes	50%	0.5	1.0	No	0	0.00%	Not relevant	0	0.00%	Not relevant	0	0.0%	Not relevant	-	0
Compliance with requirements regarding access to healthcare for people with a learning disability	N/A	0.5	1.0	No.	0	0.00%	Not relevant	0	0.00%	Not relevant	0	0.076 N/A	Not relevant	-	0
Community care - referral to treatment information completeness	50%	1.0	1.0	No	0	100.00%	Achieved	0	100.00%	Achieved	U U	100.0%	Achieved	-	0
Community care - referral information completeness	50%	1.0	1.0	No		87.60%	Achieved	-	73.50%	Achieved		73.3%	Achieved		
Community care - reterial minormation completeness Community care - activity information completeness	50%	1.0	1.0	No		72.00%	Achieved		99.80%	Achieved		99.7%	Achieved		
Community care - activity information completeness	3076	1.0	1.0	NO	0	72.00%	Adileved	0	33.00%	Acilieved	0	35.776	Adileved		0
Risk of, or actual, failure to deliver Commissioner Requested Services	N/A	4.0	Report by Exception	No	0		No	0		No	0		No		
CQC compliance action outstanding (as at 31 Dec 2013)	N/A	special	Report by Exception	No			No			Yes			No		
CQC enforcement action within last 12 months (as at 31 Dec 2013)	N/A	special	Report by Exception	No			No			No			No		
CQC enforcement action (including notices) currently in effect (as at 31 Dec 2013)	N/A	4.0	Report by Exception	No			No			No			No		
Moderate CQC concerns or impacts regarding the safety of healthcare provision (as at 31 Dec 2013)	N/A	special	Report by Exception	No			No			No			No		
Major CQC concerns or impacts regarding the safety of healthcare provision (as at 31 Dec 2013)	N/A	2.0	Report by Exception	No	0		No	0		No	0		No		
Trust unable to declare ongoing compliance with minimum standards of CQC registration	N/A	special	Report by Exception	No			No			No			No		
Result	s left to complete Total Score Overide Rating (if any	e e g		0			0			0			0 3		
Compliance Framework Indicative Governa	nce Risk Rating			GREEN			AMBER-GREEN								

For finance, that:

In Year Governance Statement from the Board of York Teaching Hospital

The board are required to respond "Confirmed" or "Not confirmed" to the following statements (see notes below)

4	The board anticipates that the trust will continue to maintain a Continuity of Service risk rating of at least 3 over the next 12 months.	Confirmed
	For governance, that:	
11	The board is satisfied that plans in place are sufficient to ensure: ongoing compliance with all existing targets (after the application of thresholds) as set out in Appendix A of the Risk Assessment Framework; and a commitment to comply with all known targets going forwards.	Confirmed
	Otherwise The board confirms that there are no matters arising in the quarter requiring an exception report to Monitor (per the Risk Assessment Framework page 21, Diagram 6) which have not already been reported.	Confirmed
	Signed on behalf of the board of directors	
	Signature Signature Signature	_
	Name Alan Rose Name Patrick Crowley	<u> </u>
	Capacity Chairman Capacity Chief Executive	<u>[</u>
	Date 31 January 2014 Date 31 January 2014	Ţ
		0
lotes:	Monitor will accept either 1) electronic signatures pasted into this worksheet or 2) hand written signatures on a paper printout of this declaration posted to Monitor to arrive by the submission deadline.	
	In the event than an NHS foundation trust is unable to confirm these statements it should NOT select 'Confirmed' in the relevant box. It must provide a response (using the section below) explaining the reasons for the absence of a full certification and the action it proposes to take to address it.	
	This may include include any significant prospective risks and concerns the foundation trust has in respect of delivering quality services and effective	
	quality governance. Monitor may adjust the relevant risk rating if there are significant issues arising and this may increase the frequency and intensity of monitoring for the NHS foundation trust.	
	The board is unable to make one of more of the confirmations in the section above on this page and accordingly responds:	
A		
В		
C		

Board Response